EARNEST Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

EARNEST Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26	Closed	-$3.37K	–	694
2023 Q3	$3.37K	Buy	+26	New	+$3.46K	﹤0.01%	900

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EARNEST Partners's JAZZ Position: Q4 2023 in Review

EARNEST Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 26 shares — an estimated $3.37K sold.

EARNEST Partners first reported a position in JAZZ in Q3 2023 and held it in 1 quarter. The position peaked at $3.37K in Q3 2023. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

EARNEST Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 26 Jazz Pharmaceuticals shares in Q4 2023, an estimated $3.37K.
EARNEST Partners first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 1 quarter.
EARNEST Partners's Jazz Pharmaceuticals position peaked at $3.37K in Q3 2023.
499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.